Literature DB >> 32388831

Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech.

Zeynep Idil Seckin1, Jennifer L Whitwell2, Rene L Utianski1, Hugo Botha1, Farwa Ali1, Joseph R Duffy1, Heather M Clark1, Mary M Machulda3, Lennon G Jordan2, Hoon-Ki Min2, Val J Lowe2, Keith A Josephs4.   

Abstract

OBJECTIVE: To describe 123I-FP-CIT (DAT scan) SPECT findings in progressive apraxia of speech (PAOS) patients and to compare those findings with progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
BACKGROUND: PAOS is a neurodegenerative syndrome in which patients present with apraxia of speech, a motor speech disorder affecting programming and planning of speech. Patients with PAOS predictably develop Parkinsonism. DAT scan is a neuroimaging tool that assesses the integrity of presynaptic dopamine transporters in striatum and is usually abnormal in PSP and CBS.
METHODS: As part of an NIH-funded grant, we performed a DAT scan on 17 PAOS patients early in the disease course. DaTQUANT software was used to quantify uptake in the left and right caudate and anterior/posterior putamen, with striatum to background ratios (SBRs). The PAOS cohort was compared to 15 PSP and 8 CBS patients.
RESULTS: Five PAOS patients (29%) showed abnormalities in at least one striatal region on DAT scan. When the five PAOS patients with abnormal DAT were compared to the PSP and CBS patients, the only difference observed was lower uptake in the posterior putamen in PSP (p = 0.03). There were no differences is putamen/caudate ratio or in symmetry of uptake, across all groups. There was also no difference in MDS-UPDRS-III scores between PAOS patients with and without abnormal DAT scans (p = 0.56).
CONCLUSIONS: Abnormal DAT scan is observed early in the disease course in approximately 30% of PAOS patients, with striatal abnormalities similar to those in PSP and CBS.

Entities:  

Keywords:  123I-FP-CIT (DAT scan) SPECT; Corticobasal syndrome (CBS); Dopamine receptor; Parkinsonism; Progressive apraxia of speech (PAOS); Progressive supranuclear palsy (PSP)

Mesh:

Substances:

Year:  2020        PMID: 32388831      PMCID: PMC7426240          DOI: 10.1007/s00415-020-09883-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Neurology       Date:  2013-06-26       Impact factor: 9.910

2.  Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: A prospective study.

Authors:  Nicolas Nicastro; Pierre R Burkhard; Valentina Garibotto
Journal:  J Neurol Sci       Date:  2017-12-01       Impact factor: 3.181

3.  Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia.

Authors:  A Kertesz; W Davidson; H Fox
Journal:  Can J Neurol Sci       Date:  1997-02       Impact factor: 2.104

4.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

5.  The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.

Authors:  Kimberly D Seifert; Jonathan I Wiener
Journal:  Am J Neurodegener Dis       Date:  2013-03-08

6.  Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.

Authors:  Stefanie Klaffke; Andrea A Kuhn; Michail Plotkin; Holger Amthauer; Daniel Harnack; Roland Felix; Andreas Kupsch
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

7.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

Review 8.  Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia.

Authors:  Bradley F Boeve; Anthony E Lang; Irene Litvan
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

9.  Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Authors:  Vicky L Marshall; Cornelia B Reininger; Moritz Marquardt; Jim Patterson; Donald M Hadley; Wolfgang H Oertel; Hani T S Benamer; Paul Kemp; David Burn; Eduardo Tolosa; Jamie Kulisevsky; Luis Cunha; Durval Costa; Jan Booij; Klaus Tatsch; K Ray Chaudhuri; Gudrun Ulm; Oliver Pogarell; Helmut Höffken; Anja Gerstner; Donald G Grosset
Journal:  Mov Disord       Date:  2009-03-15       Impact factor: 10.338

10.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

View more
  1 in total

1.  Primary Progressive Apraxia of Speech: From Recognition to Diagnosis and Care.

Authors:  Joseph R Duffy; Rene L Utianski; Keith A Josephs
Journal:  Aphasiology       Date:  2020-07-07       Impact factor: 2.773

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.